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Abstract
Toxic epidermal necrolysis (TEN) and Stevens Johnson Syndrome (SJS) are severe adverse cutaneous drug reactions
that predominantly involve the skin and mucous membranes. Both are rare, with TEN and SJS affecting approxi-
mately 1or 2/1,000,000 annually, and are considered medical emergencies as they are potentially fatal. They are
characterized by mucocutaneous tenderness and typically hemorrhagic erosions, erythema and more or less severe
epidermal detachment presenting as blisters and areas of denuded skin. Currently, TEN and SJS are considered to
be two ends of a spectrum of severe epidermolytic adverse cutaneous drug reactions, differing only by their extent
of skin detachment. Drugs are assumed or identified as the main cause of SJS/TEN in most cases, but Mycoplasma
pneumoniae and Herpes simplex virus infections are well documented causes alongside rare cases in which the
aetiology remains unknown. Several drugs are at “high” risk of inducing TEN/SJS including: Allopurinol, Trimetho-
prim-sulfamethoxazole and other sulfonamide-antibiotics, aminopenicillins, cephalosporins, quinolones, carbamaze-
pine, phenytoin, phenobarbital and NSAID’s of the oxicam-type. Genetic susceptibility to SJS and TEN is likely as
exemplified by the strong association observed in Han Chinese between a genetic marker, the human leukocyte
antigen HLA-B*1502, and SJS induced by carbamazepine. Diagnosis relies mainly on clinical signs together with the
histological analysis of a skin biopsy showing typical full-thickness epidermal necrolysis due to extensive keratino-
cyte apoptosis. Differential diagnosis includes linear IgA dermatosis and paraneoplastic pemphigus, pemphigus vul-
garis and bullous pemphigoid, acute generalized exanthematous pustulosis (AGEP), disseminated fixed bullous drug
eruption and staphyloccocal scalded skin syndrome (SSSS). Due to the high risk of mortality, management of
patients with SJS/TEN requires rapid diagnosis, evaluation of the prognosis using SCORTEN, identification and inter-
ruption of the culprit drug, specialized supportive care ideally in an intensive care unit, and consideration of immu-
nomodulating agents such as high-dose intravenous immunoglobulin therapy. SJS and TEN are severe and life-
threatening. The average reported mortality rate of SJS is 1-5%, and of TEN is 25-35%; it can be even higher in
elderly patients and those with a large surface area of epidermal detachment. More than 50% of patients surviving
TEN suffer from long-term sequelae of the disease.
Background, disease name and synonyms
Stevens-Johnson syndrome (SJS) was first described in
1922, as an acute mucocutaneous syndrome in two
young boys. The condition was characterized by severe
purulent conjunctivitis, severe stomatitis with extensive
mucosal necrosis, and purpuric macules. It became
known as SJS and was recognized as a severe mucocuta-
neous disease with a prolonged course and potentially
lethal outcome that is in most cases drug-induced, and
should be distinguished from erythema multiforme (EM)
majus. Recent clinical studies have shown that the term
‘EM majus’ should not be used to describe SJS as they
are distinct disorders [1-4].
In 1956, Alan Lyell described four patients with an
eruption resembling scalding of the skin which he called
toxic epidermal necrolysis or TEN [4]. It was only as
more patients with TEN were reported in the years fol-
lowing Lyell’s original publication, that it became clear
that TEN was drug induced, and that certain drugs such
as sulfonamides, pyrazolones, barbiturates, and antiepi-
leptics were the most frequent triggers of TEN. Increas-
ingly to date, SJS and TEN are considered to be two
ends of a spectrum of severe epidermolytic adverse cuta-
neous drug reactions, differing only by their extent of
skin detachment.* Correspondence: thomas.harr@usz.chDepartment of Dermatology, University Hospital Zurich, Switzerland
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Epidemiology
SJS and TEN are rare diseases in absolute numbers with
an incidence of 1.89 cases of TEN per million inhabi-
tants per year reported for Western Germany and Berlin
in 1996 [5]. La Grenade et al report similar results, with
1.9 cases of TEN per million inhabitants per year based
on all cases reported to the FDA AERS database in the
USA [6]. Lower incidence rates were reported by Chan
et al in Singapore [7]. Certain infectious diseases may
have an impact on the incidence of TEN, and this is
clearly the case for HIV where the annual incidence is
approximately 1000-fold higher than in the general
population, with approximately 1 case per thousand per
year in the HIV-positive population ([8]. In a study of
HIV positive patients of the greater Paris area in the
late eighties and early nineties, 15 cases of SJS/TEN
were reported in patients with AIDS compared to 0.04
expected cases [9]. In another study only ten out of
50 cases of SJS/TEN in HIV patients could be clearly
attributed to the use of medications, whereas in the
other cases a cause could not be determined due to lack
of data of drug intake or details [10].
Regional differences in drug prescription, the genetic
background of patients (HLA, metabolizing enzymes),
the coexistence of cancer, or concomitant radiotherapy
[11,12], can have an impact on the incidence of SJS
and TEN.
To a lesser extent, other infections have occasionally
been reported as the sole cause. Mycoplasma pneumo-
niae infections are widely documented to cause SJS and
TEN without initial exposure to drugs [13-15]. Further-
more, Herpes simplex virus was recognized in several
cases of SJS, especially in children [16]. Single case
reports describe Lupus erythematodes [17] or reactiva-
tion of Herpes simplex under treatment with azithromy-
cine as potential causes of SJS [18]. The occurrence of
TEN in a patient with severe aplastic anaemia after allo-
geneic haematopoietic stem cell transplantation has also
been reported [19]. However there are still cases of SJS/
TEN without any obvious identifiable cause.
Clinical Features
Acute Phase
Initial symptoms of toxic epidermal necrolysis (TEN) and
Stevens Johnson Syndrome (SJS) can be unspecific and
include symptoms such as fever, stinging eyes and dis-
comfort upon swallowing. Typically, these symptoms pre-
cede cutaneous manifestations by a few days. Early sites
of cutaneous involvement are the presternal region of the
trunk and the face, but also the palms and soles. Involve-
ment (erythema and erosions) of the buccal, genital and/
or ocular mucosa occurs in more than 90% of patients,
and in some cases the respiratory and gastrointestinal
tracts are also affected [20,21]. Ocular involvement at the
onset of disease is frequent, and can range from acute
conjunctivitis, eyelid edema, erythema, crusts, and ocular
discharge, to conjunctival membrane or pseduomembrane
formation or corneal erosion, and, in severe cases, to
cicatrizing lesions, symblepharon, fornix foreshortening,
and corneal ulceration [22,23]. The severity of acute ocu-
lar manifestation is not however predictive of late compli-
cations [24]. The morphology of early skin lesions
includes erythematous and livid macules, which may or
may not be slightly infiltrated, and have a tendency to
rapid coalescence (Table 1). The above mentioned skin
signs associated with mucosal involvement are clear dan-
ger signs and warrant the initiation of rapid diagnostic
confirmation with immediate cryosections of a skin
biopsy. Histological examination including direct immu-
nofluorescence analysis of the skin biopsy is also impor-
tant in order to rule out differential diagnoses such as
autoimmune blistering diseases, bullous fixed drug erup-
tion, acute generalized exanthematic pustulosis, and due
to its rarity in adults, to a lower extend staphyloccocal
scalded skin syndrome.
In a second phase, large areas of epidermal detach-
ment develop. In the absence of epidermal detachment,
more detailed skin examination should be performed by
exerting tangential mechanical pressure on several
erythematous zones (Nikolsky sign). The Nikolsky sign
is positive if mechanical pressure induces epidermal
detachment, but is not specific for TEN or SJS, as it can
also be positive in, for example, autoimmune bullous
skin diseases.
The extent of skin involvement is a major prognostic
factor. It should be emphasized that only necrotic skin,
which is already detached (e.g. blisters, erosions) or
detachable skin (Nikolsky positive) should be included
in the evaluation of the extent of skin involvement. Bas-
tuji-Garin et al. proposed classifying patients into three
groups according to the degree of skin detachment
(Table 1, Figure 1) [1].
Late phase and sequelae
Sequelae are common features of late phase TEN.
According to the study of Magina et al [25] following
symptoms are found: hyper- and hypopigmentation of
the skin (62.5%), nail dystrophies (37.5%), and ocular
complications. According to a study of Yip et al. 50% of
patients with TEN develop late ocular complications
including, by order of decreasing frequency, severe dry
eyes (46% of cases), trichiasis (16%), symblepharon
(14%), distichiasis (14%), visual loss (5%), entropion
(5%), ankyloblepharon (2%), lagophthalmos (2%), and
corneal ulceration (2%) [24]. Hypertrophic scars are only
seen in very few patients [26]. Long-term complications
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of mucosal involvement occur in 73% of patients who
present mucosal involvement in the acute phase, and
the mucosal sequelae involve mainly the oral and oeso-
phageal mucosa, and to a lesser extent lung and genital
mucosa [27]. In a small post SJS/TEN study seven out
of nine patients had either xerostomia or keratoconjunc-
tivitis or both, resembling Sjögren-like syndrome [28].
Additionally, another group reported a patient with
Sjögren-like pluriglandular exocrine insufficiency includ-
ing exocrine pancreatic impairment [29].
Etiology and pathogenesis
Genetic susceptibility
Genetic factors associated with drug hypersensitivity are a
complex issue that has been studied in different
populations and a variety of ethnic backgrounds. A unique
and strong association between HLA, drug hypersensitivity
and ethnic background was discovered by Chung et al.
who showed a strong association in Han Chinese between
the HLA-B*1502, SJS and carbamazepine [30]. This high
association with an odds ratio of 2504 led to further stu-
dies in a similar ethnical group of Hong Kong Han Chi-
nese with severe adverse reactions to antiepileptic drugs
[31]. Another study confirmed the susceptibility of indivi-
duals with HLA-B*1502 to carbamazepine in a Thai popu-
lation [32]. A smaller Indian based study however showed
only a weak correlation between HLA-B*1502 and carba-
mazepine induced severe drug allergy. A genetic correla-
tion could not however be shown in Japanese or
Europeans [33-35]. Indeed, in a large European study
(RegiSCAR), HLA-B genotyping was performed in patients
with severe cutaneous adverse reactions caused by the two
previously mentioned drugs (carbamazepine, allopurinol)
and another three high risk drugs (sulfamethoxazole,
lamotrigine, NSAID’s of oxicam-type). This RegiSCAR
study revealed that HLA-B*1502 is neither a marker for
carbamazepine, sulfamethoxazole, lamotrigine, or NSAID’s
of oxicam-type induced SJS/TEN nor a sufficient explana-
tion for the cause of the disease in Europeans [35,36]. This
leads to the conclusion that this genetic constellation
(HLA-B*1502) is not a population independent marker for
SJS/TEN in carbamazepine exposed individuals. Severe
cutaneous reactions in HLA-B*1502 subjects were not
only associated with the drug carbamazepine, but also, to
a lesser extent (lower odds ratio), with phenytoin and
lamotrigine [31].
A second strong association between HLA genotype
and SJS/TEN has been reported for allopurinol. Indeed,
100% of Han Chinese patients with a severe adverse
drug reaction to allopurinol were HLA-B*5801 positive
[37]. Subsequently, a strong association between SJS/
TEN and HLA-B*5801 was found in Japanese patients
[34], Thai patients [32], and also, to a lesser extent (55%
of cases), in patients of European origin [36].
Table 1 clinical features that distinguish sjs, sjs-ten overlap, and ten (adapted after 1)
Clinical entity SJS SJS-TEN overlap TEN
Primary lesions Dusky red lesions Dusky red lesions Poorly delineated erythematous plaques
Flat atypical targets Flat atypical targets Epidermal detachment
Dusky red lesions
Flat atypical targets
Distribution Isolated lesions Isolated lesions Isolated lesions (rare)
Confluence (+) on face and
trunk
Confluence (++) on face and
trunk
Confluence (+++) on face, trunk, and
elsewhere
Mucosal involvement Yes Yes Yes
Systemic symptoms Usually Always Always
Detachment (%body surface
area)
<10 10-30 >30
Figure 1 Pictural representation of SJS, SJS-TEN overlap and
TEN showing the surface of epidermal detachment (Adapted
from Fig 21.9 Bolognia and Bastuji-Garin S. et al. Arch Derm
129: 92, 1993)
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Pathomechanism of SJS/TEN
The pathogenesis of SJS/TEN is not fully understood
but is believed to be immune-mediated, as re-challen-
ging an individual with the same drug can result in
rapid recurrence of SJS/TEN [38,39]. The histopathology
of SJS/TEN lesions show that keratinocyte apoptosis fol-
lowed by necrosis is the pathogenic basis of the wide-
spread epidermal detachment observed in SJS/TEN. The
clinical, histopathological and immunological findings in
SJS/TEN support the currently prevalent concept, that
SJS and TEN are specific drug hypersensitivity reactions
in which cytotoxic T lymphocytes (CTL) play a role in
the initiation phase. Indeed, in the early phase of
disease, blister fluid contains mainly cytotoxic CD8+T
lymphocytes [40,41], suggesting that a major histocom-
patibility (MHC) class-I restricted drug presentation
leads to clonal expansion of CD8+ CTLs, and the subse-
quent - to date only incompletely understood - immune
reaction that causes SJS/TEN. These CD8+ T cells
express common cutaneous leukocyte antigen (CLA)
and are negative for CD45RA and CD28. Nassif et al.
were able to demonstrate that blister T cells from
patients exert drug specific cytototoxic activity against
both autologous B-lymphocyte cell lines and keratino-
cytes [42], and furthermore demonstrated that this cell-
mediated cytotoxicity was mediated by granzyme B. The
discrepancy between the paucity of the infiltration of
immune cells (including CTLs) in the skin of patients
with SJS/TEN and the overwhelming keratinocyte apop-
tosis has however lead to the search for cytotoxic pro-
teins and/or cytokines that may “amplify” the extent of
keratinocyte apoptosis that CTLs alone could induce
upon cell-cell contact. To date, the strongest evidence
suggests a key contribution of the cytotoxic molecules
FasL and granulysin as molecules responsible for the
disseminated keratinocyte apoptosis in SJS/TEN [43,44].
The role of the membrane form of the death ligand
FasL and its cognate death receptor Fas in the signalling
that triggers keratinocyte apoptosis is supported by
research performed using an ex-vivo experimental set
up with TEN lesional skin biopsy cryostat section over-
lays with Fas-expressing lymphoid target cells [44].
However, the functional relevance of up-regulated kera-
tinocyte membrane FasL, and thus its ability to induce
keratinocyte cell death, has been questioned by some as
the above ex-vivo demonstration of the lytic ability of
keratinocyte FasL in TEN was limited in its effect on
lymphoid target cells and not demonstrated with kerati-
nocytes as target cells. It is well known that primary
keratinocytes are sensitive to the cytolytic effect of FasL
in vitro, and this sensitivity can be further enhanced by
interferon gamma, a cytokine known to be present in
the skin during TEN [45-47]. However, it is still not
fully understood what causes the up-regulation of FasL/
Fas on keratinocytes, and how the immune system,
including T cells found in blister fluid at the onset of
disease may regulate this.
The role of soluble FasL (sFasL) in SJS/TEN remains
controversial. It appears clear now that increased levels
of sFasL can be found in the serum of patients with SJS/
TEN, and levels of sFasL are consistently elevated when
analysis is performed preceding skin detachment [48].
Soluble FasL as opoposed to membrane-bound FasL is,
however, very poorly cytolytic, and it is therefore unli-
kely to be a cause of keratinocyte apoptosis in TEN
[49]. Nevertheless, one study showed that sera of SJS/
TEN were able to induce abundant keratinocyte apopto-
sis and furthermore that peripheral blood monuclear
cells of patients stimulated by the causative drug
excreted high levels of sFasL [50], but it should be
noted that sera can contain small membrane vesicles
with membarne bound FasL that can account for the
observed activity.
Gene expression analysis of blister fluid cells, and ana-
lysis of blister fluid from patients with SJS/TEN has also
recently identified secretory granulysin (a cationic cyto-
lytic protein secreted by CTL’s, NK cells and NKT cells)
as a key molecule responsible for the induction of kera-
tinocyte death in TEN [43]. Blister fluid cells express
high levels of granulysin mRNA, the protein is found in
increased concentrations in blister fluid, and most
importantly, recombinant granulysin mimicks features of
SJS/TEN when injected intradermally in mice. The find-
ing that elevated serum granulysin levels apparently dis-
criminate between serious and non-blistering adverse
drug reactions, serum granulysin levels being normal in
the latter, lends further support an important role of
granulysin in SJS/TEN [51].
In conclusion, and based on our knowledge to date,
CD8 T-cells as well as the cytolytic molecules FasL and
granulysin are key players in the pathogenesis of SJS/
TEN. How a culprit drug in a given patient who will
develop SJS/TEN regulates the function of these key
players is the subject of ongoing research.
Drugs
Drug exposure and a resulting hypersensitivity reaction
is the cause of the very large majority of cases of SJS/
TEN. In absolute case numbers, allopurinol is the most
common cause of SJS/TEN in Europe and Israel [52],
and mostly in patients receiving daily doses of at least
200 mg.
In a case control study of patients hospitalized for SJS/
TEN in selected hospitals in France, Germany, Italy and
Portugal between 1989 and 1993, Roujeau et al. reported
that the following drugs are at increased risk of inducing
SJS/TEN when used over a short period of time: trime-
troprim-sulfamethoxazole and other sulfonamide-
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antibiotics, aminopenicillins, cephalosporins, quinolones
and chlormezanone. Among drugs usually taken for
longer periods of time (carbamazepine, phenytoin, phe-
nobarbital, valproic acid, non-steroidal antinflammatory
drugs of the oxicam-type, allopurinol and corticoster-
oids), the highest risk of induction of SJS/TEN occurs
during the first 2 months of treatment with a sharp
drop of incidence thereafter [8]. However, although
these drugs have a high relative risk compared to other
drugs, the actual risk remained low with 5 cases or less
per million users per week. A similar population was
studied between 1997 and 2001 by Mockenhaupt et al.
in a multinational case-control study in Europe covering
more than 100 million inhabitants in which special
attention was given to newly marketed drugs [53]. This
study identified nevirapine, lamotrigine, and sertraline,
as drugs with a significantly increased risk of inducing
SJS/TEN. Older drugs identified as having a high risk of
inducing SJS/TEN were sulfamethoxazol/trimethoprim
(SMX/TMP), sulfonamides (sulfasalazine, sulfadiazine,
sulfadoxine, sulfafurazole), allopurinol, carbamazepine,
phenytoin, phenobarbital, and NSAID’s of the oxicam-
type (meloxicam, piroxicam, tenoxicam). However the
incidence of SJS/TEN under treatment with valproic
acid is confounded by the concomitant use of other
drugs, such as lamotrigine [5]. Mockenhaupt et al. were
able to show that almost all cases of SJS/TEN developed
within 63 days of starting use of antiepileptic drugs, and
that the risk of developing SJS/TEN per 10 000 new
users was significantly increased for carbamazepine
(1.4 cases per 10 000 users), lamotrigine (2.5), phenobar-
bital (8.1) and phenytoine (8.3). The incidence for val-
proic acid was low compared to other antiepileptic
drugs with 0.4 cases per 10 000 users [54]. Furthermore,
studies in different populations indicate that the risk of
developing SJS/TEN is highest when the drug has been
recently initiated, and subsequently declines within 8
weeks or more of administration [5,55]. Interestingly the
long term use of glucocorticosteroids for a variety of
diseases does not change the incidence of the occur-
rence of SJS/TEN for the incriminated drugs, but it
appears that glucocorticoids lengthen the interval
between the beginning of the intake of the drug and
onset of SJS/TEN [56]. A recent survey of TEN in chil-
dren identified similar drugs to those in adults, as well
as a possibly increased susceptibility to acetaminophen
(paracetamol) [57].
Photo-induced TEN or SJS are only reported in very rare
cases. Case reports exist for hydroxchloroquine [58],
naproxene [59] and clobazam [60]. An often addressed
issue is the induction of TEN or SJS after vaccination. The
vaccine adverse event reporting system concludes that
despite the plausibility of a relationship between vaccination
and SJS/TEN, the very small number of reports compared
to the large amount of vaccinations and the benefits of vac-
cinations outweighs the potential risk of SJS/TEN [61].
Diagnosis and diagnostic methods
The diagnosis relies on the one hand on clinical symp-
toms and on the other hand on histological features.
Typical clinical signs initially include areas of erythema-
tous and livid macules on the skin, on which a positive
Nikolsky sign can be induced by mechanical pressure on
the skin, followed within minutes to hours by the onset
of epidermal detachment characterized by the develop-
ment of blisters. It should be noted, however, that the
Nikolsky sign is not specific for SJS/TEN. Mucosal,
including ocular, involvement develops shortly before or
simultaneously with skin signs in almost all cases. To
distinguish SJS, SJS-TEN and TEN the surface area of
the detachment is the main discriminating factor (Figure
1). Histological work up of immediate cryosections or
conventional formalin-fixed sections of the skin reveal-
ing wide spread necrotic epidermis involving all layers
confirms the diagnosis. In order to rule out autoimmune
blistering diseases, direct immune fluorescence staining
should be additionally performed and no immunoglobu-
lin and/or complement deposition in the epidermis and/
or the epidermal-dermal zone should be detected.
Differential diagnosis
Major differential diagnosis of SJS/TEN are autoimmune
blistering diseases, including linear IgA dermatosis and
paraneoplastic pemphigus but also pemphigus vulgaris
and bullous pemphigoid, acute generalized exanthema-
tous pustulosis (AGEP), disseminated fixed bullous drug
eruption and staphyloccocal scalded skin syndrome
(SSSS). SSSS was one of the most important differential
diagnoses in the past, but the incidence is currently very
low with 0.09 and 0.13 cases per one million inhabitants
per year [54].
Management and Therapy
Treatment in acute stage
Management in the acute stage involves sequentially
evaluating the severity and prognosis of disease, prompt
identification and withdrawal of the culprit drug(s),
rapidly initiating supportive care in an appropriate set-
ting, and eventual “specific” drug therapy as described in
detail below.
Rapid evaluation of severity and prognosis
As soon as the diagnosis of SJS or TEN has been estab-
lished, the severity and prognosis of the disease should
be determined so as to define the appropriate medical
setting for further management. In order to evaluate
prognosis in patients with SJS/TEN, the validated
SCORTEN disease severity scoring system can be used
(see section devoted to prognosis and Table 2). Patients
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with a SCORTEN score of 3 or above should be mana-
ged in an intensive care unit if possible.
Prompt withdrawal of culprit drug(s)
Prompt withdrawal of causative drugs should be a prior-
ity when blisters or erosions appear in the course of a
drug eruption. Garcia-Doval et al. have shown that the
earlier the causative drug is withdrawn, the better the
prognosis, and that patients exposed to causative drugs
with long half-lives have an increased risk of dying [62].
In order to identify the culprit drug(s) it is important to
consider the chronology of administration of the drug
and the reported ability of the drug to induce SJS/TEN.
The chronology of administration of a culprit drug, or
time between first administration and development of
SJS/TEN, is between 1 and 4 weeks in the majority of
cases. The reported ability or likelihood of a drug be the
cause of SJS/TEN can be found in Pubmed/Medline or
other appropriate sources such as the Litt’s drug erup-
tion reference manual [63].
Supportive Care
SJS/TEN is a life threatening condition and therefore
supportive care is an essential part of the therapeutic
approach [64]. A multicenter study conducted in the
USA [65], and including 15 regional burn centers with
199 admitted patients, showed that survival rate - inde-
pendent of the severity of disease (APACHE-score and
TBSA = Total body surface area) - was significantly
higher in patients who were transferred to a burn unit
within 7 days after disease-onset compared with patients
admitted after 7 days (29.8% vs 51.4% (p < 0.05)). This
positive association of early referral and survival has
been confirmed in other studies [27,66].
A single center retrospective study on the outcome of
patients after admission to a burn center identified sep-
sis at the time of admission as the most important nega-
tive prognostic factor, followed by age, and to a lesser
extent the percentage of total body surface area
involved. Co-morbidities and the use of steroids may be
important on an individual basis, but lose significance in
presence of other factors [67].
A critical element of supportive care is the manage-
ment of fluid and electrolyte requirements. Intravenous
fluid should be given to maintain urine output of 50 -
80 mL per hour with 0.5% NaCl supplemented with 20
mEq of KCl. Appropriate early and aggressive replace-
ment therapy is required in case of hyponatraemia,
hypokalaemia or hypophosphataemia which quite fre-
quently occur. Wounds should be treated conservatively,
without skin debridement which is often performed in
burn units, as blistered skin acts as a natural biological
dressing which likely favors re-epithelialization. Non-
adhesive wound dressings are used where required, and
topical sulfa containing medications should be avoided.
Drug Therapy
To date, a specific therapy for SJS/TEN that has shown
efficacy in controlled clinical trials unfortunately does
not exist. Several treatment modalities given in addition
to supportive care are reported in the literature and
these are discussed below.
- Systemic steroids were the standard treatment until
the early 1990’s, although no benefit has been proven in
controlled trials. In the absence of strong evidence of
efficacy, and due to the confusion resulting from the
numerous steroid treatment regimens reported (treat-
ment of short versus long duration, various dose regi-
mens), their use has become increasingly disputed.
A recent retrospective monocenter study suggests that a
short course “pulse” of high dose corticosteroids (dexa-
methasone) may be of benefit [68]. On the other hand,
a recent retrospective case-control study conducted by
Schneck et al. in France and Germany concluded that
corticosteroids did not show a significant effect on mor-
tality in comparison with supportive care only [69].
- Thalidomide, a medication with known anti-TNFa
activity that is immunomodulatory and anti-angiogenetic
has been evaluated for the treatment of TEN [70,71].
Unfortunately, in a double-blind, randomised, placebo-
controlled study higher mortality was observed in the
thalidomide-treated group suggesting that thalidomide is
detrimental in TEN.
- High-dose intravenous immunoglobulins. As a con-
sequence of the discovery of the anti-Fas potential of
pooled human intravenous immunoglobulins (IVIG) in
vitro [44], IVIG have been tested for the treatment of
Table 2 SCORTEN severity-of-illness score
SCORTEN Parameter Individual score SCORTEN (sum of individual scores) Predicted mortality (%)
Age > 40 years Yes = 1, No = 0 0-1 3.2
Malignancy Yes = 1, No = 0 2 12.1
Tachycardia (>120/min) Yes = 1, No = 0 3 35.8
Initial surface of epidermal detachment >10% Yes = 1, No = 0 4 58.3
Serum urea >10 mmol/l Yes = 1, No = 0 >5 90
Serum glucose >14 mmol/l Yes = 1, No = 0
Bicarbonate >20 mmol/l Yes = 1, No = 0
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TEN, and their effect reported in different non-
controlled studies. To date, numerous case reports and
12 non-controlled clinical studies containing 10 or more
patients have analyzed the therapeutic effect of IVIG in
TEN (Table 3). All except one study [72], confirm the
known excellent tolerability and a low toxic potential of
IVIG when used with appropriate precaution in patients
with potential risk factors (renal insufficiency, cardiac
insufficiency, IgA deficiency, thrombo-embolic risk) [73].
Taken together, although each study has its potential
biases and the 12 studies are not directly comparable, 9
of the 12 studies suggest that there may be a benefit of
high-dose IVIG on the mortality associated with TEN
[44,69,72,74-82]. Analysis of studies published (Table 3),
suggests that total IVIG doses of more than 2 g/kg may
be of greater benefit than doses of 2 g/Kg or less. To
determine if a dose response relationship exists, Trent
et al. analyzed the published literature between 1992
and 2006, selected all studies performed in adults in
which the dose of IVIG administered was reported for
each patient, excluded cases appearing as duplicates in
separate publications where possible, and performed a
multivariate logistic regression analysis to evaluate mor-
tality and total IVIG dose after controlling for age and
affected body surface area [83]. Although this study has
limitations stated by the authors and including publica-
tion bias, heterogeneous diagnostic definitions and
methods of each study, as well as the exclusion of 2 stu-
dies owing to lack of individual IVIG dosing data, logis-
tic regression results showed that, with each 1 g/Kg
increase in IVIG dose, there was a 4.2-fold increase in
TEN patient survival, which was statistically significant.
Patients treated with high doses of IVIG had a signifi-
cantly lower mortality compared with those treated with
lower doses, and notably the mortality was zero percent
in the subset of 30 patients treated with more than 3 g/
kg total dose of IVIG. Given the favourable side-effect
profile of IVIG and the data existing to date, in the
authors’ opinion early administration of high-dose
immunoglobulin (3 g/kg total dose given over 3-4 days)
should be considered alongside supportive care for the
treatment of toxic epidermal necrolysis, given
the absence of other validated specific therapeutic
alternatives.
The concomitant administration of corticosteroids or
immunosuppressive agents remains controversial. IVIG
has also been applied in a few children with SJS/TEN,
and two non-controlled studies suggest a possible bene-
fit [84,85].
- Ciclosporin (CsA). CsA, a calcineurin-inhibitor, is an
efficient drug in transplantation and autoimmune dis-
eases. Arevalo et al. have performed a study as a case
series with two treatment arms: CsA alone versus cyclo-
phosphamide in combination with corticosteroids.
Patients treated with CsA had significantly shorter time
to complete re-epithelialisation, and fewer patients with
multi-organ failure and death were observed [86].
A small case series with three TEN patients treated
initially with high-doses of intravenous dexamethasone
followed by CsA showed a stop in disease progression
within 72 h [87]. Other single case reports also reported
a positive effect of the use of CsA in TEN [88,89].
Recently, Valeyrie-Allanore L conducted an open,
phase II trial to determine the safety and possible bene-
fit of ciclosporin [90]. Twenty-nine patients were
included in the trial (10 SJS, 12 SJS-TEN overlap and
7 TEN), and 26 completed the treatment with CsA
administered orally (3 mg/kg/d for 10 days) and tapered
over a month. The prognostic score predicted 2.75
deaths and none occurred (p = 0.1), suggesting that,
although not statistically significant, ciclosporin may be
useful for the treatment of TEN.
- TNF antagonists. A new therapeutic approach tar-
geting the proinflammatory cytokine TNFa has been
Table 3 Summary of studies concerning IVIG for TEN
Trent Viard Prins Campione Al-Mutairi Shortt Tan Stella Rajaratnam Bachot Brown Schneck
2003 1998 2003 2003 2004 2004 2005 2007 2010 2003 2004 2008
(80) (44) (73) (76) (74) (78) (79) (82) (81) (72) (75) (69)
Study design Retro Prosp Retro Prosp Prosp Retro Retro Retro Retro Prosp Retro Retro
N/ N/ N/ N/ N/ N/ N/ Cont N/ N/ N/ Cont
Cont Cont Cont Cont Cont Cont Cont Cont Cont Cont
Patients 24 10 48 10 12 16 12 23 14 34 24 75
Detachm.(%) 44 39 45 49 58 “65” — — “44” 19 49 —
Total dose IVIG (g/kg) 4 3 3 2 2-5 2.8 2 — 3.3 2 1.6 1.9 (0.7-2.3)
Predicted mortality
(SCORTEN/APACHE*)
in %
33 — — 35 — 38 * — 35.8 36 24 28.6 25
Actual mortality in % 4 0 12 10 0 25 8 26 21 32 41.7 34
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proposed by Hunger et al. They treated one patient with
a single dose of the chimeric anti-TNFa antibody
(infliximab 5 mg/kg) and reported that disease progres-
sion stopped within 24 hours followed by a complete
re-epithelialisation within 5 days [91]. Meiss et al. report
three cases with an overlap of acute generalized
exanthematous pustulosis and TEN and treatment
response to infliximab [92]. Administration of the solu-
ble TNFa Receptor Etanercept 25 mg on days 4 and 8
after onset of TEN in a single case resulted in cessation
of epidermal detachment within 24 hours but subse-
quent death of the patient. The published data is cur-
rently insufficient to draw a conclusion on the
therapeutic potential of TNF antagonists in TEN.
- Plasmapheresis/plasma exchange (PE). PE has also
been tried in SJS/TEN, but the current data does not
allow a conclusion as to the potential of this approach
to be drawn due to the small number of patients trea-
ted, the frequent confounding factors including different
or combined treatments, and other potential biases
[93-95]. Furthermore, a small single retrospective study
using PE by Furubacke et al., which compared their case
series with two published case series serving as controls,
showed no difference in terms of mortality [96].
- Cyclophosphamide (CPP). CPP has been studied in
small case series, either in combination with other treat-
ments such as CsA [86], in conjunction with high-dose
corticosteroids [97], or alone [98]. Although a beneficial
effect of CPP is suggested by the authors of these small
trials, larger studies are needed to clarify these prelimin-
ary results with a special attention to potential side
effects.
Treatment of sequelae
Due to the often combined involvement of the skin, eyes
and mucous membranes (oral, gastrointestinal, pulmon-
ary, genital, as well as urinary), the follow up and treat-
ment of sequelae should be interdisciplinary. Special
attention should be given to the prevention of ocular
complications. Early referral to an ophthalmologist is
mandatory for assessment of the extent of eye involve-
ment and prompt treatment with topical steroids. Visual
outcome is reported to be significantly better in patients
who receive specific ophtalmological treatment during
the first week of disease [23]. Some of the ocular com-
plications have an inflammatory background and have
to be treated occasionally with ophthalmic steroids and/
or extensive lubrication of the eye [26] in order to pre-
vent progression leading ultimately to the need for cor-
neal transplantation. A small single retrospective study
with IVIG showed no significant effect on ocular com-
plications in frequency and severity, but the power of
the study was weak [99]. The benefit of local antibiotic
treatment (ointments) is not clear. Yip et al. have
reported that the use of local antibiotic treatment leads
to more late complications, including, for example, dry-
ness of the eyes [24]. Hypopharyngeal stenosis combined
with dysphagia and oesophageal strictures are long-term
complications which are difficult to treat [100,101] and
may require laryngectomy.
Allergological testing
A detailed drug history is very important when striving
to identify the culprit drug in SJS/TEN. In some cases
several drugs are possible candidates and allergological
testing can be of help in identifying the most likely can-
didate. In principle, the severity of SJS and TEN does
not allow re-challenge and intradermal testing with the
culprit drugs due to the feared risk of re-inducing a sec-
ond episode of SJS/TEN, although two case reports
describe intradermal testing without triggering of a sec-
ond episode of TEN [102,103]. Induction of SJS/TEN
has, however, been documented following local eye
treatment [104,105].
Patch-testing is an investigational option, but not a rou-
tine diagnostic option at the moment. Data from Wolk-
enstein et al. has shown that low sensitivity is a problem
with patch testing in SJS/TEN, as only two of 22 tested
patients had a relevant positive patch test [106].
Currently the focus of allergological testing lies more
on ex vivo/in vitro tests. The lymphocyte transformation
test (LTT), that measures the proliferation of T cells to
a drug in vitro has shown a sensitivity of 60-70% for
patients allergic to beta-lactam antibiotics [107]. Unfor-
tunately the sensitivity of the LTT is still very low in
SJS/TEN even if performed within one week after onset
of the disease [108].
Another recently reported approach looks for up-regu-
lation of CD69 on T-lymphocytes two days after lym-
phocyte stimulation in vitro as a sign of drug
hypersensitivity [109]. Novel in vitro methods to help
identify culprit drug in SJS/TEN are still needed [110].
Prognosis
SJS and TEN are severe and life-threatening. The aver-
age reported mortality rate of SJS is 1-5%, and of TEN
is 25-35%; it can be even higher in elderly patients and
those with a large surface area of epidermal detachment
[64]. In order to standardize the evaluation of risk and
prognosis in patients with SJS/TEN, different scoring
systems have been proposed. The SCORTEN is now the
most widely used scoring system and evaluates the fol-
lowing parameters: age, malignancy, tachycardia, initial
body surface area of epidermal detachment, serum urea,
serum glucose, and bicarbonate (Table 2) [111]. Yun
et al. reported recently that lactate dehydrogenase
(LDH) may be an additional useful parameter in the
evaluation of disease severity [112].
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More than 50% of patients surviving TEN suffer from
long-term sequelae of the disease. These include sym-
blepharon, conjunctival synechiae, entropion, ingrowth
of eyelashes, cutaneous scarring, irregular pigmentation,
eruptive nevi, and persistent erosions of the mucous
membranes, phimosis, vaginal synechiae, nail dystrophy,
and diffuse hair loss.
Abbreviations
AGEP: acute generalized exanthematous pustulosis; CLA: cutaneous
leukocyte antigen; CsA: ciclosporine; CTL: cytotoxic T lymphocytes; EM:
erythema multiforme; HLA: human leukocyte antigen; IVIG: intravenous
immunoglobuline; MHC: major histocompatibility complex; NSAID: non-
steroidal anti-inflammatory drug; SJS: Stevens Johnson syndrome; SSSS:
staphylococcal scalded skin syndrome; TEN: toxic epidermal necrolysis.
Authors’ contributions
Both authors made substantial contributions and have given final approval
to the version being published.
Competing interests
The authors declare that they have no competing interests.
Received: 30 June 2009 Accepted: 16 December 2010
Published: 16 December 2010
References
1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC: Clinical
classification of cases of toxic epidermal necrolysis, Stevens-Johnson
syndrome, and erythema multiforme. Arch Dermatol 1993, 129:92-96.
2. Fiessinger N, Rendu R: Sur un syndrome charactérisé par l’inflammation
simultanée de toutes les muqueuses externes coexistant avec une
éruption vésiculeuse des quatre membres, non douloureuse et non
recidivante. Paris médical 1917, 25:54-58.
3. Stevens AM, Johnson FC: A new eruptive fever associated with stomatitis
and ophtalmia; report of two cases in children. American Journal of
Diseases in Children 1922, 24:526-533.
4. Lyell A: Toxic epidermal necrolysis: an eruption resembling scalding of
the skin. Br J Dermatol 1956, 68:355-361.
5. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R: Risk of Stevens-
Johnson syndrome and toxic epidermal necrolysis during first weeks of
antiepileptic therapy: a case-control study. Study Group of the
International Case Control Study on Severe Cutaneous Adverse
Reactions. Lancet 1999, 353:2190-2194.
6. La Grenade L, Lee L, Weaver J, Bonnel R, Karwoski C, Governale L, Brinker A:
Comparison of reporting of Stevens-Johnson syndrome and toxic
epidermal necrolysis in association with selective COX-2 inhibitors. Drug
Saf 2005, 28:917-924.
7. Chan HL: Toxic epidermal necrolysis in Singapore, 1989 through 1993:
incidence and antecedent drug exposure. Arch Dermatol 1995,
131:1212-1213.
8. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A,
Bastuji-Garin S, Correia O, Locati F, et al: Medication use and the risk of
Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med
1995, 333:1600-1607.
9. Saiag P, Caumes E, Chosidow O, Revuz J, Roujeau JC: Drug-induced toxic
epidermal necrolysis (Lyell syndrome) in patients infected with the
human immunodeficiency virus. J Am Acad Dermatol 1992, 26:567-574.
10. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM: Severe cutaneous
reactions associated with the use of human immunodeficiency virus
medications. Acta Derm Venereol 2003, 83:1-9.
11. Aguiar D, Pazo R, Duran I, Terrasa J, Arrivi A, Manzano H, Martin J, Rifa J:
Toxic epidermal necrolysis in patients receiving anticonvulsants and
cranial irradiation: a risk to consider. J Neurooncol 2004, 66:345-350.
12. Aydin F, Cokluk C, Senturk N, Aydin K, Canturk MT, Turanli AY: Stevens-
Johnson syndrome in two patients treated with cranial irradiation and
phenytoin. J Eur Acad Dermatol Venereol 2006, 20:588-590.
13. Fournier S, Bastuji-Garin S, Mentec H, Revuz J, Roujeau JC: Toxic epidermal
necrolysis associated with Mycoplasma pneumoniae infection. Eur J Clin
Microbiol Infect Dis 1995, 14:558-559.
14. Mulvey JM, Padowitz A, Lindley-Jones M, Nickels R: Mycoplasma
pneumoniae associated with Stevens Johnson syndrome. Anaesth
Intensive Care 2007, 35:414-417.
15. Schalock PC, Dinulos JG: Mycoplasma pneumoniae-induced Stevens-
Johnson syndrome without skin lesions: fact or fiction? J Am Acad
Dermatol 2005, 52:312-315.
16. Forman R, Koren G, Shear NH: Erythema multiforme, Stevens-Johnson
syndrome and toxic epidermal necrolysis in children: a review of 10
years’ experience. Drug Saf 2002, 25:965-972.
17. Mandelcorn R, Shear NH: Lupus-associated toxic epidermal necrolysis: a
novel manifestation of lupus? J Am Acad Dermatol 2003, 48:525-529.
18. Aihara Y, Ito S, Kobayashi Y, Aihara M: Stevens-Johnson syndrome
associated with azithromycin followed by transient reactivation of
herpes simplex virus infection. Allergy 2004, 59:118.
19. Zakrzewski JL, Lentini G, Such U, Duerr A, Tran V, Guenzelmann S,
Braunschweig T, Riede UN, Koldehoff M: Toxic epidermal necrolysis:
differential diagnosis of an epidermolytic dermopathy in a
hematopoietic stem cell transplant recipient. Bone Marrow Transplant
2002, 30:331-333.
20. Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J,
Delclaux C, Roupie E, Revuz J, Roujeau JC: Pulmonary complications in
toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med
1997, 23:1237-1244.
21. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J,
Touraine R: Toxic epidermal necrolysis. Clinical findings and prognosis
factors in 87 patients. Arch Dermatol 1987, 123:1160-1165.
22. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM: Erythema
multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis:
acute ocular manifestations, causes, and management. Cornea 2007,
26:123-129.
23. Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z,
Hashimoto K, Kinoshita S: Diagnosis and treatment of Stevens-Johnson
syndrome and toxic epidermal necrolysis with ocular complications.
Ophthalmology 2009, 116:685-690.
24. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ: Ocular
manifestations and complications of Stevens-Johnson syndrome and
toxic epidermal necrolysis: an Asian series. Allergy 2007, 62:527-531.
25. Magina S, Lisboa C, Leal V, Palmares J, Mesquita-Guimaraes J:
Dermatological and ophthalmological sequels in toxic epidermal
necrolysis. Dermatology 2003, 207:33-36.
26. Sheridan RL, Schulz JT, Ryan CM, Schnitzer JJ, Lawlor D, Driscoll DN,
Donelan MB, Tompkins RG: Long-term consequences of toxic epidermal
necrolysis in children. Pediatrics 2002, 109:74-78.
27. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL: Long-term
follow-up of patients treated for toxic epidermal necrolysis. J Burn Care
Res 2006, 27:26-33.
28. Roujeau JC, Guillaume JC, Revuz J, Touraine R: Reporting adverse drug
reactions. Lancet 1985, 2:1244.
29. Saban J, Pais JR, Rodriguez JL, Boixeda D: Sjogren-like pluriglandular
exocrine insufficiency after drug-induced toxic epidermal necrolysis.
Postgrad Med J 1991, 67:195-197.
30. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT:
Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004,
428:486.
31. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MH: Association
between HLA-B*1502 allele and antiepileptic drug-induced cutaneous
reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
32. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, Chen P, Lin SY, Chen WH,
Konyoung P, Khunarkornsiri U, Auvichayapat N, Pavakul K, et al: Association
between HLA-B*1502 and carbamazepine-induced severe cutaneous
adverse drug reactions in a Thai population. Epilepsia 2010, 51:926-930.
33. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK,
Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine
hypersensitivity. Pharmacogenomics 2006, 7:813-818.
34. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J,
Furuya H, Takahashi Y, Muramatsu M, et al: HLA-B locus in Japanese
patients with anti-epileptics and allopurinol-related Stevens-Johnson
Harr and French Orphanet Journal of Rare Diseases 2010, 5:39
http://www.ojrd.com/content/5/1/39
Page 9 of 11
syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008,
9:1617-1622.
35. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E,
Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC: A marker for
Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J
2006, 6:265-268.
36. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L,
Bouwes-Bavinck JN, Sidoroff A, de Toma C, et al: A European study of
HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis
related to five high-risk drugs. Pharmacogenet Genomics 2008, 18:99-107.
37. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL,
Yang LC, Hong HS, et al: HLA-B*5801 allele as a genetic marker for
severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad
Sci USA 2005, 102:4134-4139.
38. Halevi A, Ben-Amitai D, Garty BZ: Toxic epidermal necrolysis associated
with acetaminophen ingestion. Ann Pharmacother 2000, 34:32-34.
39. Schmidt D, Kluge W: Fatal toxic epidermal necrolysis following
reexposure to phenytoin: a case report. Epilepsia 1983, 24:440-443.
40. Correia O, Delgado L, Ramos JP, Resende C, Torrinha JA: Cutaneous T-cell
recruitment in toxic epidermal necrolysis. Further evidence of CD8+
lymphocyte involvement. Arch Dermatol 1993, 129:466-468.
41. Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I,
Bensussan A, Roujeau JC: Blister fluid T lymphocytes during toxic
epidermal necrolysis are functional cytotoxic cells which express human
natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000,
119:225-230.
42. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P,
Bagot M, Roujeau JC: Toxic epidermal necrolysis: effector cells are drug-
specific cytotoxic T cells. J Allergy Clin Immunol 2004, 114:1209-1215.
43. Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC,
Chu SC, Ho HC, et al: Granulysin is a key mediator for disseminated
keratinocyte death in Stevens-Johnson syndrome and toxic epidermal
necrolysis. Nat Med 2008, 14:1343-1350.
44. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T,
Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis
by blockade of CD95 with human intravenous immunoglobulin. Science
1998, 282:490-493.
45. Matsue H, Kobayashi H, Hosokawa T, Akitaya T, Ohkawara A: Keratinocytes
constitutively express the Fas antigen that mediates apoptosis in IFN
gamma-treated cultured keratinocytes. Arch Dermatol Res 1995,
287:315-320.
46. Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L,
Boumsell L, Bensussan A, Roujeau JC: Evaluation of the potential role of
cytokines in toxic epidermal necrolysis. J Invest Dermatol 2004,
123:850-855.
47. Viard-Leveugle I, Bullani RR, Meda P, Micheau O, Limat A, Saurat JH,
Tschopp J, French LE: Intracellular localization of keratinocyte Fas ligand
explains lack of cytolytic activity under physiological conditions. J Biol
Chem 2003, 278:16183-16188.
48. Murata J, Abe R, Shimizu H: Increased soluble Fas ligand levels in patients
with Stevens-Johnson syndrome and toxic epidermal necrolysis
preceding skin detachment. J Allergy Clin Immunol 2008, 122:992-1000.
49. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, Tschopp J:
Conversion of membrane-bound Fas(CD95) ligand to its soluble form is
associated with downregulation of its proapoptotic activity and loss of
liver toxicity. J Exp Med 1998, 187:1205-1213.
50. Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H: Toxic
epidermal necrolysis and Stevens-Johnson syndrome are induced by
soluble Fas ligand. Am J Pathol 2003, 162:1515-1520.
51. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H: Granulysin as a marker
for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med
2009, 151:514-515.
52. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN,
Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC: Allopurinol is the
most common cause of Stevens-Johnson syndrome and toxic epidermal
necrolysis in Europe and Israel. J Am Acad Dermatol 2008, 58:25-32.
53. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN,
Sidoroff A, Schneck J, Roujeau JC, Flahault A: Stevens-Johnson syndrome
and toxic epidermal necrolysis: assessment of medication risks with
emphasis on recently marketed drugs. The EuroSCAR-study. J Invest
Dermatol 2008, 128:35-44.
54. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J: Risk of
Stevens-Johnson syndrome and toxic epidermal necrolysis in new users
of antiepileptics. Neurology 2005, 64:1134-1138.
55. Tennis P, Stern RS: Risk of serious cutaneous disorders after initiation of
use of phenytoin, carbamazepine, or sodium valproate: a record linkage
study. Neurology 1997, 49:542-546.
56. Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC:
Characteristics of toxic epidermal necrolysis in patients undergoing
long-term glucocorticoid therapy. Arch Dermatol 1995, 131:669-672.
57. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP,
Martin E, Kaufman DW, Maison P: Medications as risk factors of Stevens-
Johnson syndrome and toxic epidermal necrolysis in children: a pooled
analysis. Pediatrics 2009, 123:e297-304.
58. Callaly EL, FitzGerald O, Rogers S: Hydroxychloroquine-associated, photo-
induced toxic epidermal necrolysis. Clin Exp Dermatol 2008, 33:572-574.
59. Mansur AT, Aydingoz IA: A case of toxic epidermal necrolysis with lesions
mostly on sun-exposed skin. Photodermatol Photoimmunol Photomed
2005, 21:100-102.
60. Redondo P, Vicente J, Espana A, Subira ML, De Felipe I, Quintanilla E:
Photo-induced toxic epidermal necrolysis caused by clobazam. Br J
Dermatol 1996, 135:999-1002.
61. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME: Stevens-Johnson
syndrome and toxic epidermal necrolysis after vaccination: reports to
the vaccine adverse event reporting system. Pediatr Infect Dis J 2001,
20:219-223.
62. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC: Toxic
epidermal necrolysis and Stevens-Johnson syndrome: does early
withdrawal of causative drugs decrease the risk of death? Arch Dermatol
2000, 136:323-327.
63. Litt JZ: Litt’s Drug Eruptions and Reactions Manual., 16 2010.
64. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N
Engl J Med 1994, 331:1272-1285.
65. Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC,
Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, et al: A multicenter
review of toxic epidermal necrolysis treated in U.S. burn centers at the
end of the twentieth century. J Burn Care Rehabil 2002, 23:87-96.
66. McGee T, Munster A: Toxic epidermal necrolysis syndrome: mortality rate
reduced with early referral to regional burn center. Plast Reconstr Surg
1998, 102:1018-1022.
67. Ducic I, Shalom A, Rising W, Nagamoto K, Munster AM: Outcome of
patients with toxic epidermal necrolysis syndrome revisited. Plast
Reconstr Surg 2002, 110:768-773.
68. Kardaun SH, Jonkman MF: Dexamethasone pulse therapy for Stevens-
Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007,
87:144-148.
69. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M:
Effects of treatments on the mortality of Stevens-Johnson syndrome
and toxic epidermal necrolysis: A retrospective study on patients
included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008,
58:33-40.
70. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L,
Maignan M, Schuhmacher MH, Milpied B, Pilorget A, et al: Randomised
comparison of thalidomide versus placebo in toxic epidermal necrolysis.
Lancet 1998, 352:1586-1589.
71. Namazi MR: Increased mortality in toxic epidermal necrolysis with
thalidomide: corroborating or exonerating the pathogenetic role of TNF-
alpha? Br J Dermatol 2006, 155:842-843.
72. Bachot N, Revuz J, Roujeau JC: Intravenous immunoglobulin treatment for
Stevens-Johnson syndrome and toxic epidermal necrolysis: a
prospective noncomparative study showing no benefit on mortality or
progression. Arch Dermatol 2003, 139:33-36.
73. Prins C, Gelfand EW, French LE: Intravenous immunoglobulin: properties,
mode of action and practical use in dermatology. Acta Derm Venereol
2007, 87:206-218.
74. Al-Mutairi N, Arun J, Osama NE, Amr Z, Mazen AS, Ibtesam el A, Nazeha
el B: Prospective, noncomparative open study from Kuwait of the role of
intravenous immunoglobulin in the treatment of toxic epidermal
necrolysis. Int J Dermatol 2004, 43:847-851.
75. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL: Toxic
epidermal necrolysis: does immunoglobulin make a difference? J Burn
Care Rehabil 2004, 25:81-88.
Harr and French Orphanet Journal of Rare Diseases 2010, 5:39
http://www.ojrd.com/content/5/1/39
Page 10 of 11
76. Campione E, Marulli GC, Carrozzo AM, Chimenti MS, Costanzo A, Bianchi L:
High-dose intravenous immunoglobulin for severe drug reactions:
efficacy in toxic epidermal necrolysis. Acta Derm Venereol 2003,
83:430-432.
77. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN,
Flynn K, Trent J, Margolis DJ, et al: Treatment of toxic epidermal necrolysis
with high-dose intravenous immunoglobulins: multicenter retrospective
analysis of 48 consecutive cases. Arch Dermatol 2003, 139:26-32.
78. Shortt R, Gomez M, Mittman N, Cartotto R: Intravenous immunoglobulin
does not improve outcome in toxic epidermal necrolysis. J Burn Care
Rehabil 2004, 25:246-255.
79. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK: High-dose intravenous
immunoglobulins in the treatment of toxic epidermal necrolysis: an
Asian series. J Dermatol 2005, 32:1-6.
80. Trent JT, Kirsner RS, Romanelli P, Kerdel FA: Analysis of intravenous
immunoglobulin for the treatment of toxic epidermal necrolysis using
SCORTEN: The University of Miami Experience. Arch Dermatol 2003,
139:39-43.
81. Rajaratnam R, Mann C, Balasubramaniam P, Marsden JR, Taibjee SM, Shah F,
Lim R, Papini R, Moiemen N, Lewis H: Toxic epidermal necrolysis:
retrospective analysis of 21 consecutive cases managed at a tertiary
centre. Clin Exp Dermatol 2010, 35(8):853-862.
82. Stella M, Clemente A, Bollero D, Risso D, Dalmasso P: Toxic epidermal
necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with
high-dose intravenous immunoglobulins and topical conservative
approach. A retrospective analysis. Burns 2007, 33:452-459.
83. Trent JT, Fangchao M, Kerdel F, Fie S, French LE, Romanelli p, Kirsner RS:
Dose of intravenous immunoglobulin and patient survival in SJS and
toxic epidermal necrolysis. Expert Review of Dermatology 2007, 2:299-303.
84. Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC: Efficacy of low dose
intravenous immunoglobulins in children with toxic epidermal
necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol
2005, 71:398-400.
85. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ: Treatment of
toxic epidermal necrolysis with intravenous immunoglobulin in children.
J Am Acad Dermatol 2002, 47:548-552.
86. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J: Treatment of
toxic epidermal necrolysis with cyclosporin A. J Trauma 2000, 48:473-478.
87. Rai R, Srinivas CR: Suprapharmacologic doses of intravenous
dexamethasone followed by cyclosporine in the treatment of toxic
epidermal necrolysis. Indian J Dermatol Venereol Leprol 2008, 74:263-265.
88. Hashim N, Bandara D, Tan E, Ilchyshyn A: Early cyclosporine treatment of
incipient toxic epidermal necrolysis induced by concomitant use of
lamotrigine and sodium valproate. Acta Derm Venereol 2004, 84:90-91.
89. Robak E, Robak T, Gora-Tybor J, Chojnowski K, Strzelecka B,
Waszczykowska E, Sysa-Jedrzejowska A: Toxic epidermal necrolysis in a
patient with severe aplastic anemia treated with cyclosporin A and G-
CSF. J Med 2001, 32:31-39.
90. Valeyrie-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J,
Bagot M, Roujeau J: Open trial of ciclosporin treatment for Stevens-
Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010,
163(4):847-853.
91. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N: Rapid
resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J
Allergy Clin Immunol 2005, 116:923-924.
92. Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch W, Fischer M: Overlap
of acute generalized exanthematous pustulosis and toxic epidermal
necrolysis: response to antitumour necrosis factor-alpha antibody
infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007,
21:717-719.
93. Kamanabroo D, Schmitz-Landgraf W, Czarnetzki BM: Plasmapheresis in
severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985,
121:1548-1549.
94. Lissia M, Figus A, Rubino C: Intravenous immunoglobulins and
plasmapheresis combined treatment in patients with severe toxic
epidermal necrolysis: preliminary report. Br J Plast Surg 2005, 58:504-510.
95. Yamada H, Takamori K, Yaguchi H, Ogawa H: A study of the efficacy of
plasmapheresis for the treatment of drug induced toxic epidermal
necrolysis. Ther Apher 1998, 2:153-156.
96. Furubacke A, Berlin G, Anderson C, Sjoberg F: Lack of significant treatment
effect of plasma exchange in the treatment of drug-induced toxic
epidermal necrolysis? Intensive Care Med 1999, 25:1307-1310.
97. Frangogiannis NG, Boridy I, Mazhar M, Mathews R, Gangopadhyay S, Cate T:
Cyclophosphamide in the treatment of toxic epidermal necrolysis. South
Med J 1996, 89:1001-1003.
98. Heng MC, Allen SG: Efficacy of cyclophosphamide in toxic epidermal
necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol
1991, 25:778-786.
99. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ: High-dose
intravenous immunoglobulin in the treatment of toxic epidermal
necrolysis: a study of ocular benefits. Eye (Lond) 2005, 19:846-853.
100. Barrera JE, Meyers AD, Hartford EC: Hypopharyngeal stenosis and
dysphagia complicating toxic epidermal necrolysis. Arch Otolaryngol Head
Neck Surg 1998, 124:1375-1376.
101. Herman TE, Kushner DC, Cleveland RH: Esophageal stricture secondary to
drug-induced toxic epidermal necrolysis. Pediatr Radiol 1984, 14:439-440.
102. Romano A, Di Fonso M, Pocobelli D, Giannarini L, Venuti A, Garcovich A:
Two cases of toxic epidermal necrolysis caused by delayed
hypersensitivity to beta-lactam antibiotics. J Investig Allergol Clin Immunol
1993, 3:53-55.
103. Tagami H, Tatsuta K, Iwatski K, Yamada M: Delayed hypersensitivity in
ampicillin-induced toxic epidermal necrolysis. Arch Dermatol 1983,
119:910-913.
104. Asensio-Sanchez VM: [Toxic epidermal necrolysis following dorzolamide
eyedrops]. An Med Interna 2008, 25:47-48.
105. Schmutz JL, Barbaud A, Trechot P: [Polymorphous bullous erythema and
trihexiphenidyl (or why police questioning is not always the most
productive method)]. Ann Dermatol Venereol 2007, 134:899.
106. Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L,
Revuz J, Roujeau JC: Patch testing in severe cutaneous adverse drug
reactions, including Stevens-Johnson syndrome and toxic epidermal
necrolysis. Contact Dermatitis 1996, 35:234-236.
107. Pichler WJ, Tilch J: The lymphocyte transformation test in the diagnosis
of drug hypersensitivity. Allergy 2004, 59:809-820.
108. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T: Utility of the
lymphocyte transformation test in the diagnosis of drug sensitivity:
dependence on its timing and the type of drug eruption. Allergy 2007,
62:1439-1444.
109. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ: CD69 upregulation
on T cells as an in vitro marker for delayed-type drug hypersensitivity.
Allergy 2008, 63:181-188.
110. Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N,
Pichler WJ: In vitro detection of cytotoxic T and NK cells in peripheral
blood of patients with various drug-induced skin diseases. Allergy 2009,
65(3):376-84.
111. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J,
Wolkenstein P: SCORTEN: a severity-of-illness score for toxic epidermal
necrolysis. J Invest Dermatol 2000, 115:149-153.
112. Yun SJ, Choi MS, Piao MS, Lee JB, Kim SJ, Won YH, Lee SC: Serum lactate
dehydrogenase is a novel marker for the evaluation of disease severity
in the early stage of toxic epidermal necrolysis. Dermatology 2008,
217:254-259.
doi:10.1186/1750-1172-5-39
Cite this article as: Harr and French: Toxic epidermal necrolysis and
Stevens-Johnson syndrome. Orphanet Journal of Rare Diseases 2010 5:39.
Harr and French Orphanet Journal of Rare Diseases 2010, 5:39
http://www.ojrd.com/content/5/1/39
Page 11 of 11
